Publications by authors named "Jenny M Thies"

Purpose: Sequencing-based genetic testing often identifies variants of uncertain significance (VUS) or fails to detect pathogenic variants altogether. We evaluated the utility of RNA sequencing (RNA-seq) to clarify VUS or identify missing variants in a clinical setting.

Methods: Over a 2-year period, genetics providers at a single institution referred 26 cases for clinical RNA-seq.

View Article and Find Full Text PDF

Background: Patients with severe long-chain fatty acid oxidation disorders (LC-FAODs) experience serious morbidity and mortality despite traditional dietary management including medium-chain triglyceride (MCT)-supplemented, low-fat diets. Triheptanoin is a triglyceride oil that is broken down to acetyl-coenzyme A (CoA) and propionyl-CoA, which replenishes deficient tricarboxylic acid cycle intermediates. We report the complex medical and nutrition management of triheptanoin therapy initiated emergently for 3 patients with LC-FAOD.

View Article and Find Full Text PDF
Article Synopsis
  • Glycosylation is essential for the immune system's development and function, with abnormalities linked to issues like antibody deficiency and lymphocyte signaling problems.
  • Human MGAT2 is a key gene in the production of complex N-glycans, necessary for immune functionality, and mutations can lead to disorders like MGAT2-CDG, which causes severe developmental issues and various medical complications.
  • A case study of a 4-year-old girl with a novel mutation in MGAT2 highlights unique clinical features and contrasts with previous cases, enhancing the understanding of MGAT2-CDG’s genetic and phenotypic diversity.
View Article and Find Full Text PDF

Exome sequencing (ES) has revolutionized molecular diagnosis in children with genetic disease over the past decade. However, exome sequencing in the inpatient setting has traditionally been discouraged, in part due to an increased risk of providers failing to retrieve and act upon results, as many patients are discharged before results return. The development of rapid turn-around-times (TATs) for genomic testing has begun to shift this paradigm.

View Article and Find Full Text PDF